Immunotherapy slows the progression of type 1 diabetes

Immunotherapy slows the progression of type 1 diabetes

The drug "Teplizumab" can be used to inhibit immunity, stopping the development of the first type of diabetes. The discovery is a scientific breakthrough that could change the lives of hundreds of thousands of people.

Teplizumab, which inhibits the body's immune system, can slow the progression of type 1 diabetes. It has been shown from the follow-up effect of this drug, it is allowed in the production of insulin and it slows down the development of type I diabetes on average for two years.

Type 1 diabetes usually begins in childhood, so it is necessary to have a way to stop its growth or slow its development. Clinical trials were conducted with the participation of 76 children and adolescents aged 8-18 years. All of these are within the risk group, because their relatives have the disease. Tiblisomate, which has been injected with intravenous feeder once every two weeks, has slowed the destruction of insulin-producing cells.

The first type of diabetes has nothing to do with a person's lifestyle and weight. This disease is hereditary and all sufferers are forced throughout their lives to use insulin injections.

Source: Medicom Forum


Nawfal Mohammed

Hello I am a student at law college and I am still studying i'M GOOG IN : Blogging, MMA fighter, Designer, Website Management, Bodybuilding, etc BUT my Hobbies :Learn languages, horseback riding, motorcycles and more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker